1. Introduction {#s0005}
===============

Mental health is in part dependent upon transcriptional responses to cues which can be environmental, chemical, physiological and psychological; this is termed the Gene×Environment (G×E) component. These changes not only affect our health in the short term, but can have medium to long term impact via epigenetic modulation of gene expression, altering our response to environmental challenges. Genetic polymorphism can modulate the G×E response and offer insight into the mechanisms underpinning such pathways ([@bib38]). Earlier genetic studies targeted association of one genetic variant to a specific disorder; this had limited success and focused predominantly on candidate genes such as those in the monoaminergic pathways. These correlations are now being readdressed by analysing multiple variants in such pathways or by stratification of the cohorts based on environmental factors. Our recent work on a promoter polymorphism of the monoamine oxidase A gene and maternal parameters affecting infant behaviour is an example of the latter ([@bib15]). It is difficult to address the signal cascade in response to specific challenges in vivo due to the heterogeneity of cells involved in processing the environmental signals mediating a cellular response. However, in vitro cell line models offer an opportunity to address in fine detail the signal pathways modulated in response to a specific challenge. In this study we analysed the response to distinct drugs in the human neuroblastoma cell line SH-SY5Y targeting a commercially available compilation of mood disorder genes to address whether they leave a molecular signature of transcriptional change to the challenge. The drugs chosen for comparison included two psychostimulant challenges, amphetamine and cocaine, and two mood stabilisers, sodium valproate and lithium. All of these drugs have been shown previously to modulate signal pathways in SH-SY5Y cells at the transcriptional and/or post-transcriptional level ([@bib4; @bib8; @bib19; @bib23; @bib32; @bib48]). Our analysis identified similarities and differences in the networks modified by the drug challenge which suggested an overlap in the pathways of the mood stabilisers. These changes reflect one window for the spectrum of changes that could occur in vivo, but nonetheless outline the potential for a concerted cellular response to drug exposure.

2. Materials and methods {#s0010}
========================

2.1. Cell culture and drug treatment {#s0015}
------------------------------------

Human derived SH-SY5Y neuroblastoma cells (American Type Culture Collection) were maintained in Earle׳s modified Eagle׳s medium (EMEM) (Sigma) and HAM׳s F12 (Sigma) at a ratio of 1:1, supplemented with 10% foetal calf serum (FCS) (Sigma), 1% 200 mM [l]{.smallcaps}-glutamine, 1% 100 mM sodium pyruvate and 100 U/ml penicillin/100 ug/ml streptomycin at 37 °C and 5% CO~2~. Amphetamine, cocaine hydrochloride, lithium chloride and valproic acid sodium salt were purchased from Sigma and stock solutions made using sterile filtered dH~2~O. Drug regimes were 1 h treatment with either: vehicle control (sterile filtered dH~2~O), 10 µM amphetamine ([@bib18; @bib41]), 10 µM cocaine ([@bib48]), 1 mM lithium ([@bib16; @bib39]) or 5 mM sodium valproate ([@bib32; @bib33; @bib52]). For each drug treatment, *n*=4. Basal (untreated) cells were also included.

2.2. RNA extraction and quantitative polymerase chain reaction (qPCR) analysis {#s0020}
------------------------------------------------------------------------------

Total RNA was extracted using Trizol reagent (Invitrogen) and the resulting RNA pellets resuspended in RNase-free water. 500 ng RNA was reverse transcribed into cDNA using the GoScript™ RT system (Promega). qPCR analysis was performed on an iQ5 real-time PCR system (Bio-Rad) using 1 µl of cDNA per reaction and GoTaq^®^ qPCR Master Mix (Promega) with the addition of Fluorescene Calibration Dye (Bio-Rad) at a final concentration of 10 nM. Changes in gene expression were analysed on the Lonza Web site (<http://array.lonza.com/gpr>), using the Global Pattern Recognition™ (GPR) analysis software designed by Bar Harbor Biotechnology (<https://www.bhbio.com/BHB/dw/home.html>). This algorithm internally normalised the real-time qPCR data set of each gene with respect to all genes within the experiment and generated a list of genes that are ranked on the basis of the difference between the test and control expression levels and the consistency of the data between the biological replicates. This proprietary software calculated both the fold-change data and the respective *p*-values. The results are displayed as change with respect to the genes that showed minimal changes, which were defined on Ct values obtained using the Global Pattern Recognition analysis software ([@bib3]).

A list of genes on the mood array is presented in [Table 1](#t0005){ref-type="table"}.

2.3. Bioinformatic analysis {#s0025}
---------------------------

Gene expression data generated from GPR analysis was uploaded into the online biological pathway analysis software MetaCore™, version 6.15 build 62452. Functional enrichment of the experimental dataset was performed using: 1) the Pathway Map analysis tool to identify significantly associated pathways based on *p*-value and GPR Fold-change and 2) Build Network for Your Experimental Data feature using the Transcription Factor Targets Modelling algorithm with default settings under Analyse Networks (Transcription Factors) to generate sub-networks based on the presence of transcription factors and/or receptor targets within the original input file. Such genes/proteins uploaded from experimental datasets and from which pathways were built upon were termed 'seed nodes'.

In silico analysis of NRSF binding sites over the significantly altered genes across the different treatment conditions from the qPCR array data were identified using Transcription Factor ChIP-seq from ENCODE (Encyclopaedia of DNA Elements), version 4, available on the UCSC Genome Browser (<http://genome.ucsc.edu/index.html>). Upstream and downstream flank sequences (10 Kb) were included and the position of NRSF binding sites calculated. For genes with multiple transcripts, the locus for the largest isoform was used. The full list of NRSF binding sites is detailed in [Table 3](#t0015){ref-type="table"}.

3. Results {#s0030}
==========

3.1. Gene expression profiling of human SH-SY5Y cells in response to mood-modifying drugs using Global Pattern Recognition analysis {#s0035}
-----------------------------------------------------------------------------------------------------------------------------------

To investigate the effects of mood modifying drugs on the expression of a panel of genes associated with mood disorders (Human Mood Disorder 96 StellARray™), SH-SY5Y neuroblastoma cells after treatment for 1 h under one of the specified conditions were analysed using the proprietary Global Pattern Recognition (GPR) algorithm which compares the change in expression of a gene normalised to the expression of every other gene in the array ([@bib3]). This software calculates both the fold-change data and the respective *p*-values with respect to genes that showed minimal changes. We and others have recently demonstrated that drugs used in the treatment of mood disorders can differentially affect the expression stability of traditionally used housekeeping genes, impacting upon their usefulness as normalising factors ([@bib7; @bib34; @bib44]). Unfortunately, these large changes in gene expression may mask small but biologically important changes in gene expression, such as master regulator genes (e.g., transcription factors). The data in [Table 2](#t0010){ref-type="table"} therefore represents a more appropriate display of the genes most changed within the experiment by comparing all genes against themselves. As the array contains validated mood genes we addressed the top 10 genes which significantly changed in response to each drug to define pathways and networks within the larger gene list.

Following treatment with the mood stabiliser sodium valproate, 8 genes were significantly (*p*\<0.05) up- or down-regulated compared to the vehicle control; 2 up-regulated (JUN and PAFAH1B3) and 6 down-regulated (DRD3, GAD1, NRG1, PER3, RELN and RGS4). When compared to the results obtained after treatment with another common mood stabiliser, lithium, similarities in the gene expression profile with respect to the top 10 altered genes were observed; namely down-regulation of GAD1, NRG1, PER3, RELN and RGS4, but, only GAD1 reached statistical significance at this time point for lithium treatment. In addition, FOS was significantly down-regulated in response to lithium. Treatment with the two psychomotor stimulants cocaine and amphetamine demonstrated no statistically significant changes in gene expression following 1 h treatment. Furthermore the genes with the lowest *p*-values were distinct between the psychostimulants apart from MOBP ([Table 2](#t0010){ref-type="table"}) demonstrating that these drugs might be preferentially targeting distinct pathways for their action. However due to the low *p*-values obtained under these experimental conditions we did not pursue their analysis further.

3.2. Network analysis of genes significantly modulated in response to mood stabilisers {#s0040}
--------------------------------------------------------------------------------------

To further explore potential gene networks important in the response to drug challenge, we analysed only the genes whose expression was most affected by lithium and sodium valproate using the Analyse Networks (Transcription Factors) algorithm from MetaCore™. This generates sub-networks through relative enrichment of the uploaded dataset based on the presence of transcription factors and/or receptor targets within the original input file. The gene set used was composed of GAD1, NRG1, PER3, RELN, RGS4, PAFAH1B3, DRD3, FOS and JUN, the first five of which were observed for both lithium and sodium valproate and the remaining were those significantly modified in response to either exposure.

A network containing NRSF, ErbB2 and ErbB3 as seed nodes was the highest ranked using this approach, and was defined as genes/proteins uploaded from experimental datasets or genes/proteins directly linked to uploaded gene lists from which networks are built ([Fig. 1](#f0005){ref-type="fig"}). It included 7 of our 9 input genes (DRD3, FOS, GAD1, JUN, NRG1, PAFAH1B3 and RELN) and had a *p*-value of 5.24×10^−29^ based on hypergeometric distribution which calculated the probability of a particular pathway map arising by chance given the number of genes across all gene pathways, within a particular pathway or sub-network and within the present experimental dataset. The transcription factors identified as being important regulators of this network were c-Fos and c-Jun (collectively AP-1), c-Myc, ESR1, NRSF, PR, RAR-alpha and SP3.

As our gene expression data showed that 7/9 of the significantly modulated genes were down-regulated ([Table 2](#t0010){ref-type="table"}) and NRSF which predominantly functions as a transcriptional repressor was identified as an important regulator of our gene set, we addressed predicted NRSF binding sites using ENCODE data from the Transcription Factor ChIP-seq track ([@bib1]; [@bib40]) on the UCSC Genome Browser. This identified NRSF binding at the promoter regions (within 5 Kb of the transcriptional start site) of DRD3 (transcript variant a, e and g), FOS, GAD1, JUN, NRG1 (transcript variant HRG-gamma1/2/3, HRG-beta1/d-, 2- and 3b, ndf43/b/c, HRG-alpha and SMDF), PAFAH1B3 and RGS4 (transcript variant 2/3) which, with the exception of JUN and PAFAH1B3, were all down-regulated in response to 1 h treatment with sodium valproate (or lithium with respect to FOS).

To determine how these regulatory pathways were most relevant for mood disorders, we filtered our dataset using the MetaCore™ 'Filter by Disease' feature which traces all of the known associated interactions for a particular disease process. This assigned 46.15% of our network, not unexpectedly to disease processes relating to mood ([Fig. 2](#f0010){ref-type="fig"}A). Furthermore, it identified NRSF and ERK1/2 signalling along the oestrogen receptor pathway as important regulators of processes relevant to mood disorders involving this subset of genes. In addition to disorders of the CNS, filtering of our dataset by disease showed there to be significant associations (96.15%) with breast, skin and gastrointestinal neoplasia; GAD1 being the only gene not to be involved in these cancer-related pathologies ([Fig. 2](#f0010){ref-type="fig"}B). To further assess which signalling pathways may be operating in response to challenge with these mood stabilisers, we also filtered our experimental network for Drug Responses under the Gene Ontology (GO) Processes filter. This identified the fibroblast growth factor, ERBB and neurotrophin TRK receptor signalling pathways as important cellular responses, with the dopamine D3 receptor, EGFR, ErbB2, ErbB3 and c-Src highlighted as therapeutic targets ([Fig. 2](#f0010){ref-type="fig"}C).

4. Discussion {#s0045}
=============

Understanding the mechanism of action for a drug to alter the cell phenotype, in addition to the initial cellular targets recognised by the drug, is important for both clinical application and pharmaceutical development. Transcriptome profiling allows for global scale interrogation of potential regulatory mechanisms involved in modulating cellular responses to a particular drug through the use of pathway analysis tools. The aim of this study was to address the effects of mood modifying drugs on the expression profile of a commercially available panel of genes associated with mood disorders by network analysis to compare and contrast their mode of action.

We used two mood stabilisers (lithium and sodium valproate) and two mood stimulants (cocaine and amphetamine). Only the mood stabilisers reached statistical significance and interestingly they shared 5 genes in their top 9 most modified genes, [Table 2](#t0010){ref-type="table"}; we therefore focused on this set of genes for further analysis. Valproate significantly modified 8 genes, lithium only two, GAD1 and FOS, with GAD1 being significantly down-regulated for both drugs. GAD1 encodes one of several forms of glutamic acid decarboxylase which is a key enzyme for the synthesis of the inhibitory neurotransmitter GABA. GAD1 is implicated from both genetic and functional analysis as a modulator of mood ([@bib9; @bib14; @bib21; @bib26; @bib46; @bib49]). FOS and JUN proteins constitute the AP-1 transcription factor complex which was a target for modulation. These factors represent a family of proteins that heterodimerise to regulate the AP-1 DNA site ([@bib35; @bib36; @bib37; @bib45]). Lithium and sodium valproate have both been demonstrated to modulate the AP-1 complex ([@bib6; @bib31]). The genes shared in common by the mood stabilisers sodium valproate and lithium were GAD1, NRG1, PER3, RELN and RGS4. The remainder, DRD3, JUN and PAFAH1B3 were specific for sodium valproate. Although some of these genes were modified with cocaine and amphetamine, the statistical significance was low, certainly lower than all the genes in the 9 most differentially expressed genes in [Table 2](#t0010){ref-type="table"}. We have previously used cocaine and amphetamine in SH-SY5Y and found that we can observe significant changes in genes involved in mental health. For example, recently in the approximate same passage number of cells as used in this experiment, we have demonstrated that cocaine altered the expression of the schizophrenia candidate gene MIR137 ([@bib48]). However under the current experimental conditions this gene set targeting mood disorders is not responding as robustly to cocaine and amphetamine as lithium and sodium valproate. We therefore attempted to determine whether the significant mood stabiliser gene set defined a specific pathway or network of genes to explain their concerted response to drug exposure.

Pathway analysis using both the Analyse Networks (Transcription Factors) and Filter by Disease algorithms available on the online pathway analysis software MetaCore™ identified the transcription factor NRSF, also termed REST (repressor element-1 silencing transcription factor), to be strongly associated with the pathways supporting these networks of genes. NRSF has a direct association with DRD3, GAD1 and RELN genes based on the network analysis, [Fig. 1](#f0005){ref-type="fig"}. Bioinformatic analysis of predicted NRSF binding sites using ENCODE (Encyclopaedia of DNA Elements) data from the Transcription Factor ChIP-seq track ([@bib1]; [@bib40]) on the UCSC Genome Browser identified NRSF binding at the promoter regions (within 5 Kb of the transcriptional start site) of the FOS, NRG1 and RGS4 genes, [Table 3](#t0015){ref-type="table"}. This ENCODE analysis also demonstrated NRSF binding sites in similar genomic locations on DRD3, GAD1, JUN, PAFAH1B3 and RELN. Aberrant signalling of NRSF and its target genes has been shown to be involved in the pathophysiology of several CNS disorders including schizophrenia ([@bib24]), major depressive disorder ([@bib30]) and alcoholism and depression ([@bib47]), with genetic variants influencing age-related cognitive function ([@bib28]). More recently it has been highlighted as a major player in Alzheimer׳s disease ([@bib25]). NRSF has the properties to modulate epigenetic factors in its target genes due to its association with a plethora of co-activators, such as members of the SWI/SNF family, which can modify histones by post-translational modifications ([@bib24]). These epigenetic modifications could result in medium to long term changes in gene expression that underlie drug exposure in addition to the immediate modulation of the transcriptome. Our data suggest that lithium and sodium valproate, with different initial cellular targets, may modulate related signalling pathways leading to overlapping cellular responses mediated in part by the NRSF pathway. It should be noted that we performed this experiment at 1 h postexposure to capture an early response of the cell to the drug. As in any stimulus induction modification of gene expression many of these changes will be transient, especially in the short term for transcription factors such as AP-1 and NRSF. This is in keeping with the transient response of AP-1 and NRSF in stimulus inducible gene expression models we have previously observed at 1 h postexposure ([@bib13; @bib17; @bib35; @bib42]). A more extensive timescale would perhaps have demonstrated a different or related set of genes, nevertheless, our strategy allowed the observation of the differential gene set acting as a signature for the mood stabilisers and allows for future optimisation.

Filtering our dataset by disease also identified ERK1/2 signalling along with the oestrogen receptor pathway as a potentially important regulatory network for this gene set (Fig. 2). Oestrogen receptor signalling has been well documented in the modulation of behaviours relating to aggression ([@bib29]), anxiety and depression ([@bib11]). The action of sex hormones may in part explain why in conditions such as panic disorder these phenotypes are more prevalent among females. Our data would be consistent with GAD1 SNP variation being tentatively associated for the higher susceptibility of females to panic disorder ([@bib49]) via modulation by oestrogen. This oestrogen pathway could overlap with other transcription factor pathways identified in our analysis, for example synergistic action of the oestrogen and AP-1 pathways on gene expression ([@bib10]). The extended networks identified in this study (AP-1, oestrogen and NRSF) may also work synergistically, for example NRSF activity is important for E2 stimulation of the cell cycle ([@bib5]) and oestrogen receptor B is enriched at NRSF binding sites ([@bib22]). Such interactions between these three pathways can be further modified by the glucocorticoid receptor, so linking these pathways to a major driver of mood ([@bib2; @bib20]). Glucocorticoid sensitivity is strongly associated with several mood related disorders ([@bib43]) and anti-glucocorticoid drugs have been used in the treatment of such conditions ([@bib12; @bib50; @bib51]). Mood disorder susceptibility has also been linked to glucocorticoid signalling through its modulation of the stress response along the hypothalamic--pituitary--adrenal (HPA) axis ([@bib27; @bib43]).

Our data points to a cost effective and rapid assessment of expression changes in selected genes using GPR analysis, which can help delineate the pathways targeted by drugs to modify mood. In particular, we have identified dopamine and glutamine pathways as being important; perhaps not unexpectedly as the gene set is enriched for known genes involved in mood disorders. Alteration in the regulation of these pathways would be expected to modulate mood and is reflected in the range of drugs currently used in targeting these pathways. However the modulation of the AP-1 pathway and the involvement of factors such as NRSF and ERK1/2 highlight a more general modulation of neurotransmitter pathways in response to mood modifying drugs. Our model can therefore be used to determine mechanisms associated with off target and long term affects of particular drugs and can be extrapolated to predict in vivo responses, utilised in the comparison of multiple drug regimes or used as an initial screening process to inform optimal drug design.
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![Network analysis of genes significantly modulated in response to mood stabilisers. Genes shown to be significantly up or down regulated in human SH-SY5Y cells in response to 1 h treatment with the mood stabilisers sodium valproate and lithium were uploaded into MetaCore™ for network analysis. The gene list was analysed under the Build Network feature using the Transcription Factor Targets Modelling algorithm. Seed nodes from which the network was built upon are encompassed by a large circle; blue circles represent genes from the experimental data, green circles represent molecules from which the pathway is expanded from and red circles represent molecules on which the pathway terminates. Genes uploaded from the experimental data are also marked with a smaller circle in their top right hand corner; red circles represent genes that were significantly up-regulated, whereas blue circles represent genes significantly down-regulated. Connecting arrows indicate interactions; green arrows represent activation, red arrows represent inhibition and blue arrows are unspecified. Overlaid cyan lines represent canonical pathways. Gene names/symbols within the network from top to bottom, left to right: Neuregulin 1, Dopamine D3 receptor, RELN, ErbB3, ErbB2, EGFR, Shc, GRB2, MEK1/2, c-Raf-1, GAD1 PAFAH gamma, SOS, c-Src, H-Ras, ERK1/2, NRSF, SP3, c-Myc, ESR1 (nuclear), c-Fos, c-Jun/c-Fos, JunD/c-Fos, RARalpha, PR (nuclear) c-Jun, and AP-1. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![Network analysis filters for disease and gene ontology processes. The network generated in relation to genes significantly regulated in response to SH-SY5Y cell treatment with sodium valproate and lithium ([Fig. 1](#f0005){ref-type="fig"}) was filtered to show the relevant disease pathways (A and B) and gene ontology processes (C). (A and B) Disease processes relevant to mood disorders (A), represents 46.15% of the gene network; and breast, skin and gastrointestinal neoplasms (B), represents 96.15% of the gene network. (C) Gene ontology processes relevant to drug response. Seed nodes from which the network was built upon are encompassed by a large blue circle. Genes uploaded from the experimental data are also marked with a smaller circle in their top right hand corner; red circles represent genes that were significantly up-regulated, whereas blue circles represent genes significantly down-regulated. Connecting blue arrows indicate direct interactions, yellow arrows indicate interactions that are in the base but do not form part of the network and overlaid cyan lines represent canonical pathways. Gene names/symbols within network A, from top to bottom, left to right: Neuregulin 1, Dopamine D3 receptor, Reelin, ERK1/2, MEK1/2, NRSF, ESR1 (nuclear), c-Fos, c-Jun/c-Fos, JunD/c-Fos, PR (nuclear) and AP-1; B, from top to bottom, left to right: Neuregulin 1, Dopamine D3 receptor, Reelin, ErbB3, ErbB2, EGFR, SOS, Shc, GRB2, c-Raf-1, PAFAH gamma, H-Ras, c-Src, ERK1/2, MEK1/2, NRSF, SP3, c-Myc, ESR1 (nuclear), c-Fos, c-Jun/c-Fos, JunD/c-Fos, RARalpha, PR (nuclear), c-Jun and AP-1; and C, from top to bottom, left to right: Dopamine D3 receptor, Reelin, ErbB3, ErbB2, EGFR, GAD1, c-Src, NRSF, c-Myc, c-Fos, c-Jun/c-Fos, JunD/c-Fos, c-Jun and AP-1. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#f0010}

###### 

Gene name and description for the Human Mood Disorder 96-well qPCR StellARray™.

  Gene name    Entrez gene   Description
  ------------ ------------- -------------------------------------------------------------------------------------------
  ACE          1636          Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
  ADCYAP1      116           Adenylate cyclase activating polypeptide 1 (pituitary)
  ADRBK2       157           Adrenergic, beta, receptor kinase 2
  ARNTL        406           Aryl hydrocarbon receptor nuclear translocator-like
  ATP2A2       488           ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
  BCR          613           Breakpoint cluster region
  BDNF         627           Brain-derived neurotrophic factor
  CASP8        841           Caspase 8, apoptosis-related cysteine peptidase
  CCND2        894           Cyclin D2
  CHRNA7       1139          Cholinergic receptor, nicotinic, alpha 7
  CIT          11113         Citron rho-interacting serine/threonine kinase
  CLOCK        9575          Clock circadian regulator
  COMT         1312          Catechol-O-methyltransferase
  CREB1        1385          CAMP responsive element binding protein 1
  CRH          1392          Corticotropin releasing hormone
  CRHBP        1393          Corticotropin releasing hormone binding protein
  DAO          1610          [d]{.smallcaps}-amino-acid oxidase
  DISC1        27185         Disrupted in schizophrenia 1
  DLX1         1745          Distal-less homeobox 1
  DRD1         1812          Dopamine receptor D1
  DRD3         1814          Dopamine receptor D3
  DRD4         1815          Dopamine receptor D4
  DTNBP1       84062         Dystrobrevin binding protein 1
  ERBB3        2065          V-erb-b2 erythroblastic leukemia viral oncogene homolog 3
  FAT1         2195          FAT atypical cadherin 1
  FKBP5        2289          FK506 binding protein 5
  FOS          2353          FBJ murine osteosarcoma viral oncogene homolog
  GABRA5       2558          Gamma-aminobutyric acid (GABA) A receptor, alpha 5
  GAD1         2571          Glutamate decarboxylase 1 (brain, 67 kDa)
  GCH1         2643          GTP cyclohydrolase 1
  GPR50        9248          G protein-coupled receptor 50
  GRIK3        2899          Glutamate receptor, ionotropic, kainate 3
  GRIK4        2900          Glutamate receptor, ionotropic, kainate 4
  GRIN2B       2904          Glutamate receptor, ionotropic, N-methyl [d]{.smallcaps}-aspartate 2B
  GRM3         2913          Glutamate receptor, metabotropic 3
  GRM4         2914          Glutamate receptor, metabotropic 4
  GSK3B        2932          Glycogen synthase kinase 3 beta
  Hs18s        --            Human 18S ribosomal RNA
  HS Genomic   --            Human genomic DNA control
  HSP90B1      7184          Heat shock protein 90 kDa beta (Grp94), member 1
  HSPA5        3309          Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
  HTR1B        3351          5-hydroxytryptamine (serotonin) receptor 1B
  HTR2A        3356          5-hydroxytryptamine (serotonin) receptor 2A
  IL1RN        3557          Interleukin 1 receptor antagonist
  IMPA1        3612          Inositol(myo)-1(or 4)-monophosphatase 1
  IMPA2        3613          Inositol(myo)-1(or 4)-monophosphatase 2
  INPP1        3628          Inositol polyphosphate-1-phosphatase
  ISYNA1       51477         Myo-inositol 1-phosphate synthase A1
  JUN          3725          Jun oncogene
  KCNN3        3782          Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3
  MAG          27307         Malignancy-associated gene
  MAL          4118          Mal, T-cell differentiation protein
  MAOA         4128          Monoamine oxidase A
  MLC1         23209         Megalencephalic leukoencephalopathy with subcortical cysts 1
  MOBP         4336          Myelin-associated oligodendrocyte basic protein
  MOG          4340          Myelin oligodendrocyte glycoprotein
  MTHFR        4524          5,10-methylenetetrahydrofolate reductase (NADPH)
  NAPG         8774          N-ethylmaleimide-sensitive factor attachment protein, gamma
  NCAM1        4684          Neural cell adhesion molecule 1
  ND4          4538          Mitochondrially encoded NADH dehydrogenase 4
  NDUFV1       4723          NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa
  NDUFV2       4729          NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa
  NOS1AP       9722          Nitric oxide synthase 1 (neuronal) adaptor protein
  NR1D1        9572          Nuclear receptor subfamily 1, group D, member 1
  NR3C1        2908          Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  NRG1         3084          Neuregulin 1
  NTRK2        4915          Neurotrophic tyrosine kinase, receptor, type 2
  OLIG2        10215         Oligodendrocyte lineage transcription factor 2
  P2RX7        5027          Purinergic receptor P2X, ligand-gated ion channel, 7
  PAFAH1B1     5048          Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45 kDa
  PAFAH1B3     5050          Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa
  PCNT         5116          Pericentrin
  PDLIM5       10611         PDZ and LIM domain 5
  PER3         8863          Period circadian clock 3
  PIP4K2A      5305          Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha
  PLA2G1B      5319          Phospholipase A2, group IB (pancreas)
  PLA2G4A      5321          Phospholipase A2, group IVA (cytosolic, calcium-dependent)
  PLCG1        5335          Phospholipase C, gamma 1
  PLP1         5354          Proteolipid protein 1
  POLG         5428          Polymerase (DNA directed), gamma
  PTGS2        5743          Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
  RELN         5649          Reelin
  RFX4         5992          Regulatory factor X, 4 (influences HLA class II expression)
  RGS4         5999          Regulator of G-protein signaling 4
  SLC12A6      9990          Solute carrier family 12 (potassium/chloride transporters), member 6
  SLC6A2       6530          Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
  SLC6A3       6531          Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
  SLC6A4       6532          Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
  SULT1A1      6817          Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1
  SYNGR1       9145          Synaptogyrin 1
  TAAR6        319100        Trace amine associated receptor 6
  TF           7018          Transferrin
  TIMELESS     8914          Timeless circadian clock
  TPH1         7166          Tryptophan hydroxylase 1 (tryptophan 5-monooxygenase)
  TPH2         121278        Tryptophan hydroxylase 2
  XBP1         7494          X-box binding protein 1

###### 

Gene expression profiling of SH-SY5Y cells following exposure to drugs affecting mood.

  Lithium    Sodium valproate                                                                                                                                                                                                         
  ---------- -------------------------------------------------------------------------------- ----------- ------------- -------------- ---------------------------------------------------------------------------------- ----------- -------------
  **FOS**    **FBJ murine osteosarcoma viral oncogene homolog**                               **0.012**   **−2.57**     **DRD3**       **Dopamine receptor D3**                                                           **0.001**   **−7.98**
  **GAD1**   **Glutamate decarboxylase 1**                                                    **0.023**   **−3.48**     **RGS4**       **Regulator of G-protein signaling 4**                                             **0.007**   **−2.08**
  RGS4       Regulator of G-protein signaling 4                                               0.063       −1.51         **JUN**        **Jun oncogene**                                                                   **0.008**   **2.49**
  PER3       Period circadian clock 3                                                         0.067       −1.38         **RELN**       **Reelin**                                                                         **0.012**   **−1.78**
  NRG1       Neuregulin 1                                                                     0.068       −1.43         **PER3**       **Period circadian clock 3**                                                       **0.026**   **−1.48**
  NR1D1      Nuclear receptor subfamily 1, group D, member 1                                  0.069       −1.48         **PAFAH1B3**   **Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa**   **0.034**   **1.61**
  RELN       Reelin                                                                           0.078       −1.94         **GAD1**       **Glutamate decarboxylase 1**                                                      **0.035**   **−7.45**
  ACE        Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1                       0.099       1.31          **NRG1**       **Neuregulin 1**                                                                   **0.044**   **−1.34**
  Hs18s      Human 18S ribosomal RNA                                                          0.105       1.64          MTHFR          Methylenetetrahydrofolate reductase (NADPH)                                        0.083       1.53
  BDNF       Brain-derived neurotrophic factor                                                0.106       −1.39         RFX4           Regulatory factor X, 4 (influences HLA class II expression)                        0.092       −1.49
                                                                                                                                                                                                                                      
  Cocaine    Amphetamine                                                                                                                                                                                                              
  Gene       Description                                                                      *p*         Fold change   Gene           Description                                                                        *p*         Fold change
  SULT1A1    Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1              0.088       1.68          MOBP           Myelin-associated oligodendrocyte basic protein                                    0.080       2.08
  DRD3       Dopamine receptor D3                                                             0.110       −2.08         XBP1           X-box binding protein 1                                                            0.093       1.34
  FOS        FBJ murine osteosarcoma viral oncogene homolog                                   0.142       −1.45         NR1D1          Nuclear receptor subfamily 1, group D, member 1                                    0.109       −1.35
  MOBP       Myelin-associated oligodendrocyte basic protein                                  0.161       1.85          MAG            Malignancy-associated gene                                                         0.138       2.81
  SLC6A2     Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2   0.176       −1.28         PAFAH1B3       Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa       0.141       1.33
  GRIK3      Glutamate receptor, ionotropic, kainate 3                                        0.194       −1.67         FKBP5          FK506 binding protein 5                                                            0.159       −1.34
  TIMELESS   Timeless circadian clock                                                         0.200       −1.20         RELN           Reelin                                                                             0.198       −1.30
  NCAM1      Neural cell adhesion molecule 1                                                  0.206       −1.20         BCR            Breakpoint cluster region                                                          0.207       1.22
  ND4        Mitochondrially encoded NADH dehydrogenase 4                                     0.232       1.15          MLC1           Megalencephalic leukoencephalopathy with subcortical cysts 1                       0.208       2.52
  NR1D1      Nuclear receptor subfamily 1, group D, member 1                                  0.233       −1.28         GABRA5         Gamma-aminobutyric acid (GABA) A receptor, alpha 5                                 0.213       −1.78
                                                                                                                                                                                                                                      

Top 10 changes in gene expression levels between treated (10 µM amphetamine, 10 µM cocaine, 1 mM lithium and 5 mM sodium valproate) and untreated conditions measured using qPCR arrays (Human Mood Disorder 96 StellARrayTM) and Global Pattern Recognition (GPR) statistical analysis. Fold change values are represented as treated conditions normalised to the drug vehicle. Bold font indicates significant changes in gene expression, *p*\<0.05.

###### 

Predicted NRSF regulation of genes affecting mood.

  Gene           Locus                        Strand   NRSF site                    Size (Bp)   Position
  -------------- ---------------------------- -------- ---------------------------- ----------- ----------
  ACE            chr17:61554422--61575741     \+       chr17:61553914--61554174     260         −508
  ACE            chr17:61554422--61575741     \+       chr17:61554504--61554774     270         82
  ACE            chr17:61554422--61575741     \+       chr17:61556270--61556594     324         1848
  ACE            chr17:61554422--61575741     \+       chr17:61557174--61557444     270         2752
  ACE            chr17:61554422--61575741     \+       chr17:61558309--61558579     270         3887
  ADRBK2         chr22:25960861--26125258     \+       chr22:25961290--25961560     270         429
  ADRBK2         chr22:25960861--26125258     \+       chr22:26052841--26053085     244         91980
  ADRBK2         chr22:25960861--26125258     \+       chr22:26097050--26097320     270         136189
  ARNTL          chr11:13277734--13387266     \+       chr11:13283216--13283586     370         5482
  ARNTL          chr11:13277734--13387266     \+       chr11:13298458--13299341     883         20724
  ARNTL          chr11:13277734--13387266     \+       chr11:13310624--13311040     416         32890
  ARNTL          chr11:13277734--13387266     \+       chr11:13312905--13313275     370         35171
  ARNTL          chr11:13277734--13387266     \+       chr11:13351630--13351900     270         73896
  ARNTL          chr11:13277734--13387266     \+       chr11:13361071--13361575     504         83337
  ARNTL          chr11:13277734--13387266     \+       chr11:13364729--13364973     244         86995
  ARNTL          chr11:13277734--13387266     \+       chr11:13365612--13366116     504         87878
  BCR            chr22:23522552--23660224     \+       chr22:23525622--23525892     270         3070
  BCR            chr22:23522552--23660224     \+       chr22:23546679--23546949     270         24127
  BCR            chr22:23522552--23660224     \+       chr22:23562075--23562399     324         39523
  BCR            chr22:23522552--23660224     \+       chr22:23566052--23566322     270         43500
  BCR            chr22:23522552--23660224     \+       chr22:23591914--23592184     270         69362
  BCR            chr22:23522552--23660224     \+       chr22:23624008--23624332     324         101456
  BCR            chr22:23522552--23660224     \+       chr22:23647903--23648174     271         125351
  BCR            chr22:23522552--23660224     \+       chr22:23651156--23651400     244         128604
  BDNF           chr11:27676442--27743605     −        chr11:27667673--27667943     270         −8499
  BDNF           chr11:27676442--27743605     −        chr11:27671454--27671716     262         −4726
  BDNF           chr11:27676442--27743605     −        chr11:27680076--27680346     270         63259
  BDNF           chr11:27676442--27743605     −        chr11:27721240--27721484     244         22121
  BDNF           chr11:27676442--27743605     −        chr11:27723005--27723329     324         20276
  BDNF           chr11:27676442--27743605     −        chr11:27739843--27740167     324         3438
  BDNF           chr11:27676442--27743605     −        chr11:27740692--27741122     430         2483
  BDNF           chr11:27676442--27743605     −        chr11:27741795--27742502     707         1103
  BDNF           chr11:27676442--27743605     −        chr11:27742701--27743071     370         534
  BDNF           chr11:27676442--27743605     −        chr11:27743607--27744258     651         +2
  BDNF           chr11:27676442--27743605     −        chr11:27744566--27744890     324         +961
  CASP8          chr2:202098166--202152434    \+       chr2:202096900--202097280    380         −1266
  CASP8          chr2:202098166--202152434    \+       chr2:202098061--202098441    380         −105
  CASP8          chr2:202098166--202152434    \+       chr2:202122713--202123093    380         24547
  CRH            chr8:67088612--67090846      −        chr8:67089099--67090281      1182        565
  CRH            chr8:67088612--67090846      −        chr8:67090287--67090659      372         187
  CRH            chr8:67088612--67090846      −        chr8:67090956--67091280      324         +110
  CRH            chr8:67088612--67090846      −        chr8:67091915--67092285      370         +1069
  CRH            chr8:67088612--67090846      −        chr8:67098519--67098889      370         +7673
  DISC1          chr1:231762561--232177019    \+       chr1:231795960--231796330    370         33399
  DISC1          chr1:231762561--232177019    \+       chr1:231814930--231815200    270         52369
  DISC1          chr1:231762561--232177019    \+       chr1:231925791--231926295    504         163230
  DISC1          chr1:231762561--232177019    \+       chr1:231963016--231963520    504         200455
  DISC1          chr1:231762561--232177019    \+       chr1:231964053--231964309    256         201492
  DISC1          chr1:231762561--232177019    \+       chr1:232067746--232067990    244         305185
  DISC1          chr1:231762561--232177019    \+       chr1:232148522--232148892    370         385961
  **DRD3**       chr3:113847557--113918254    −        chr3:113871366--113871690    324         46564
  **DRD3**       chr3:113847557--113918254    −        chr3:113874262--113874642    380         43612
  **DRD3**       chr3:113847557--113918254    −        chr3:113897607--113898013    406         20241
  **DRD3**       chr3:113847557--113918254    −        chr3:113898443--113898813    370         19441
  DRD4           chr11:637305--640705         \+       chr11:640330--640654         324         3025
  DTNBP1         chr6:15523032--15663289      −        chr6:15552018--15552288      270         111001
  DTNBP1         chr6:15523032--15663289      −        chr6:15621994--15622224      230         41065
  DTNBP1         chr6:15523032--15663289      −        chr6:15662506--15662830      324         459
  FKBP5          chr6:35541362--35696397      −        chr6:35656504--35656848      344         39549
  FKBP5          chr6:35541362--35696397      −        chr6:35687515--35687759      244         8638
  FKBP5          chr6:35541362--35696397      −        chr6:35695292--35695562      270         835
  FKBP5          chr6:35541362--35696397      −        chr6:35695873--35696103      230         294
  FKBP5          chr6:35541362--35696397      −        chr6:35699743--35700105      362         −3346
  **FOS**        chr14:75745481--75748937     \+       chr14:75743830--75744074     244         −1651
  **FOS**        chr14:75745481--75748937     \+       chr14:75745296--75745800     504         −185
  GABRA5         chr15:27111866--27194357     \+       chr15:27110041--27110545     504         −1825
  GABRA5         chr15:27111866--27194357     \+       chr15:27111625--27112129     504         −241
  **GAD1**       chr2:171673200--171717659    \+       chr2:171670663--171671101    438         −2537
  **GAD1**       chr2:171673200--171717659    \+       chr2:171671290--171671546    256         −1910
  **GAD1**       chr2:171673200--171717659    \+       chr2:171672190--171672567    377         −1010
  **GAD1**       chr2:171673200--171717659    \+       chr2:171679546--171679776    230         6346
  **GAD1**       chr2:171673200--171717659    \+       chr2:171701873--171702253    380         28673
  GRIK3          chr1:37261128--37499844      −        chr1:37269486--37269856      370         229988
  GRIK3          chr1:37261128--37499844      −        chr1:37301874--37302144      270         197700
  GRIK3          chr1:37261128--37499844      −        chr1:37329834--37330078      244         169766
  GRIK3          chr1:37261128--37499844      −        chr1:37331752--37332256      504         167588
  GRIK3          chr1:37261128--37499844      −        chr1:37332540--37332784      244         167060
  GRIK3          chr1:37261128--37499844      −        chr1:37388506--37388750      244         111094
  GRIK3          chr1:37261128--37499844      −        chr1:37389788--37390253      465         109591
  GRIK3          chr1:37261128--37499844      −        chr1:37411488--37411732      244         88112
  GRIK3          chr1:37261128--37499844      −        chr1:37431706--37432281      575         67563
  GRIK3          chr1:37261128--37499844      −        chr1:37486267--37486654      387         13190
  GRIK3          chr1:37261128--37499844      −        chr1:37494616--37494860      244         4984
  GRIK3          chr1:37261128--37499844      −        chr1:37504779--37505043      264         −4935
  GRM3           chr7:86273230--86494192      \+       chr7:86290343--86290599      256         17113
  GRM3           chr7:86273230--86494192      \+       chr7:86322086--86322456      370         48856
  GRM3           chr7:86273230--86494192      \+       chr7:86476174--86476554      380         202944
  GRM3           chr7:86273230--86494192      \+       chr7:86497476--86497720      244         +3284
  **JUN**        chr1:59246463--59249785      −        chr1:59249472--59249885      413         −100
  MAG            chr19:35782989--35820133     \+       chr19:35796870--35797100     230         13881
  MAG            chr19:35782989--35820133     \+       chr19:35809956--35810280     324         26967
  MAOA           chrX:43515409--43606068      \+       --                           --          --
  MLC1           chr22:50497820--50523781     −        --                           --          --
  MOBP           chr3:39543557--39567857      \+       chr3:39540121--39540386      265         −3436
  MOBP           chr3:39543557--39567857      \+       chr3:39558349--39558719      370         14792
  MOBP           chr3:39543557--39567857      \+       chr3:39574318--39574698      380         +6461
  MTHFR          chr1:11845787--11866160      −        chr1:11845214--11845454      240         +573
  MTHFR          chr1:11845787--11866160      −        chr1:11850982--11851306      324         14854
  MTHFR          chr1:11845787--11866160      −        chr1:11856563--11856793      230         9367
  MTHFR          chr1:11845787--11866160      −        chr1:11857775--11857960      185         8200
  MTHFR          chr1:11845787--11866160      −        chr1:11858618--11858699      81          7461
  MTHFR          chr1:11845787--11866160      −        chr1:11863764--11864034      270         2126
  MTHFR          chr1:11845787--11866160      −        chr1:11865502--11865882      380         278
  MTHFR          chr1:11845787--11866160      −        chr1:11866038--11866425      387         −265
  NAPG           chr18:10525873--10552766     \+       chr18:10525815--10526242     427         −58
  NCAM1          chr11:112831969--113092626   \+       chr11:112831909--112832179   270         −60
  NCAM1          chr11:112831969--113092626   \+       chr11:112977293--112977549   256         145324
  NCAM1          chr11:112831969--113092626   \+       chr11:113008930--113009200   270         176961
  NCAM1          chr11:112831969--113092626   \+       chr11:113011853--113012123   270         179884
  NCAM1          chr11:112831969--113092626   \+       chr11:113023160--113023664   504         191191
  NCAM1          chr11:112831969--113092626   \+       chr11:113074175--113074445   270         242206
  NR1D1          chr17:38249037--38256973     −        chr17:38244467--38244847     380         +4570
  NR1D1          chr17:38249037--38256973     −        chr17:38254215--38254595     380         2378
  NR1D1          chr17:38249037--38256973     −        chr17:38255228--38255666     438         1307
  NR1D1          chr17:38249037--38256973     −        chr17:38256685--38257094     409         −121
  NR1D1          chr17:38249037--38256973     −        chr17:38257324--38257828     504         −351
  NR1D1          chr17:38249037--38256973     −        chr17:38264445--38264769     324         −7472
  NR3C1          chr5:142657496--142783254    −        chr5:142784785--142785394    609         −2140
  **NRG1**       chr8:31496911--32622558      \+       chr8:31499444--31499814      370         2533
  **NRG1**       chr8:31496911--32622558      \+       chr8:31612484--31612740      256         115573
  **NRG1**       chr8:31496911--32622558      \+       chr8:31629195--31629565      370         132284
  **NRG1**       chr8:31496911--32622558      \+       chr8:31652781--31653242      461         155870
  **NRG1**       chr8:31496911--32622558      \+       chr8:31691004--31691508      504         194093
  **NRG1**       chr8:31496911--32622558      \+       chr8:31817830--31818086      256         320919
  **NRG1**       chr8:31496911--32622558      \+       chr8:31896212--31896582      370         399301
  **NRG1**       chr8:31496911--32622558      \+       chr8:32084240--32084744      504         587329
  **NRG1**       chr8:31496911--32622558      \+       chr8:32122327--32122831      504         625416
  **NRG1**       chr8:31496911--32622558      \+       chr8:32189091--32189595      504         692180
  **NRG1**       chr8:31496911--32622558      \+       chr8:32191794--32192298      504         694883
  **NRG1**       chr8:31496911--32622558      \+       chr8:32200953--32201685      732         704042
  **NRG1**       chr8:31496911--32622558      \+       chr8:32245491--32245735      244         748580
  **NRG1**       chr8:31496911--32622558      \+       chr8:32276508--32276752      244         779597
  **NRG1**       chr8:31496911--32622558      \+       chr8:32284202--32284706      504         787291
  **NRG1**       chr8:31496911--32622558      \+       chr8:32392615--32392985      370         895704
  **NRG1**       chr8:31496911--32622558      \+       chr8:32405958--32406282      324         909047
  **NRG1**       chr8:31496911--32622558      \+       chr8:32406492--32406892      400         909581
  **NRG1**       chr8:31496911--32622558      \+       chr8:32411341--32411845      504         914430
  **NRG1**       chr8:31496911--32622558      \+       chr8:32487206--32487506      300         990295
  **NRG1**       chr8:31496911--32622558      \+       chr8:32488853--32489109      256         991942
  **NRG1**       chr8:31496911--32622558      \+       chr8:32503654--32504024      370         1006743
  **NRG1**       chr8:31496911--32622558      \+       chr8:32546371--32546746      375         1049460
  **NRG1**       chr8:31496911--32622558      \+       chr8:32572641--32573145      504         1075730
  **NRG1**       chr8:31496911--32622558      \+       chr8:32581201--32581705      504         1084290
  **NRG1**       chr8:31496911--32622558      \+       chr8:32582687--32583047      360         1085776
  **PAFAH1B3**   chr19:42801185--42806952     −        chr19:42806435--42806939     504         −13
  **PER3**       chr1:7844714--7905237        \+       \~14 Kb upstream of 5׳UTR    --          --
  PDLIM5         chr4:95373038--95509370      \+       chr4:95372903--95373283      380         −135
  PDLIM5         chr4:95373038--95509370      \+       chr4:95406777--95407007      230         33739
  PDLIM5         chr4:95373038--95509370      \+       chr4:95418920--95419164      244         45882
  PDLIM5         chr4:95373038--95509370      \+       chr4:95455973--95456203      230         82935
  PDLIM5         chr4:95373038--95509370      \+       chr4:95456267--95456511      244         83229
  PDLIM5         chr4:95373038--95509370      \+       chr4:95471601--95471831      230         98563
  PDLIM5         chr4:95373038--95509370      \+       chr4:95499407--95499663      256         126369
  **RELN**       chr7:103112231--103629963    −        chr7:103127865--103128245    380         501718
  **RELN**       chr7:103112231--103629963    −        chr7:103276613--103276992    379         352971
  **RELN**       chr7:103112231--103629963    −        chr7:103297949--103298179    230         331784
  **RELN**       chr7:103112231--103629963    −        chr7:103301028--103301258    230         328705
  **RELN**       chr7:103112231--103629963    −        chr7:103354935--103355205    270         274758
  **RELN**       chr7:103112231--103629963    −        chr7:103438111--103438481    370         191482
  **RELN**       chr7:103112231--103629963    −        chr7:103451010--103451107    97          178856
  **RELN**       chr7:103112231--103629963    −        chr7:103484281--103484449    168         145514
  **RELN**       chr7:103112231--103629963    −        chr7:103491745--103492249    504         137714
  **RELN**       chr7:103112231--103629963    −        chr7:103559848--103560078    230         69885
  **RELN**       chr7:103112231--103629963    −        chr7:103580845--103581215    370         48748
  **RELN**       chr7:103112231--103629963    −        chr7:103636658--103636861    203         −6898
  RFX4           chr12:106976685--107156582   \+       chr12:106975282--106975646   364         −1403
  RFX4           chr12:106976685--107156582   \+       chr12:106975776--106976119   343         −909
  RFX4           chr12:106976685--107156582   \+       chr12:107147300--107147544   244         170615
  **RGS4**       chr1:163038396--163046592    \+       chr1:163039054--163039341    287         658
  SLC12A6        chr15:34522197--34630265     −        chr15:34516950--34517512     562         +5247
  SLC12A6        chr15:34522197--34630265     −        chr15:34610582--34611086     504         19179
  SLC12A6        chr15:34522197--34630265     −        chr15:34630069--34630393     324         −128
  SLC12A6        chr15:34522197--34630265     −        chr15:34634991--34635543     552         −4726
  SLC6A2         chr16:55689542--55737700     \+       chr16:55686047--55686317     270         −3495
  SLC6A2         chr16:55689542--55737700     \+       chr16:55689638--55689908     270         96
  SLC6A2         chr16:55689542--55737700     \+       chr16:55690575--55690845     270         1033
  SLC6A2         chr16:55689542--55737700     \+       chr16:55693927--55694197     270         4385
  SLC6A2         chr16:55689542--55737700     \+       chr16:55695818--55696088     270         6276
  SLC6A2         chr16:55689542--55737700     \+       chr16:55696686--55696956     270         7144
  SLC6A2         chr16:55689542--55737700     \+       chr16:55744402--55744761     359         +7061
  SLC6A2         chr16:55689542--55737700     \+       chr16:55746277--55746521     244         +8821
  SLC6A4         chr17:28523378--28562954     −        --                           --          --
  SULT1A1        chr16:28616908--28634907     −        chr16:28621167--28621407     240         13500
  TF             chr3:133419211--133497850    \+       chr3:133461483--133461863    380         42272
  TF             chr3:133419211--133497850    \+       chr3:133465027--133465407    380         45816
  TF             chr3:133419211--133497850    \+       chr3:133472690--133472920    230         53479
  TIMELESS       chr12:56810157--56843200     −        chr12:56811537--56811907     370         31293
  TIMELESS       chr12:56810157--56843200     −        chr12:56842752--56843263     511         −63
  TPH2           chr12:72332626--72426221     \+       chr12:72332400--72332889     489         −226
  TPH2           chr12:72332626--72426221     \+       chr12:72374868--72375372     504         42242
  TPH2           chr12:72332626--72426221     \+       chr12:72410895--72411165     270         78269
  XBP1           chr22:29190548--29196560     −        chr22:29196394--29196960     566         −400
  XBP1           chr22:29190548--29196560     −        chr22:29198252--29198482     230         −1922
                                                                                                

NRSF binding sites over top 10 affected genes across all drug treatments from Transcription Factor ChIP-seq from ENCODE version 4. Bold font indicates genes significantly affected by drug challenge. Negative and positive values under Position represent the location of the NRSF site upstream of the gene transcriptional start site and downstream of the 3׳UTR, respectively. Values not assigned +/− represent binding sites within the gene sequence. For genes with multiple transcripts, binding site positions are with respect to the largest isoform.
